Intelligent Bio Solutions

Q1 FY2027 EarningsQ1 FY27 results were largely in line with revenue expectations at $1.39M (vs. $1.40M consensus) and delivered a significant beat on gross margin at 54.46% (vs. 52.00% expected). While the GAAP net loss of $2.66M was slightly wider than the $2.62M consensus, GAAP EPS of -$0.86 beat the -$1.31 estimate due to a higher weighted average share count from recent equity financing. The quarter was highlighted by 25% YoY revenue growth and the submission of the 510(k) premarket notification to the FDA, though the 'Going Concern' warning remains a critical headwind.